Psychological DistresstAVNS4HESNCT07411846
tAVNS for Stress Reduction in University Students
A study testing taVNS in people with Psychological Distress and Stress (Psychology), run by Egas Moniz - Cooperativa de Ensino Superior, CRL at 1 site in Portugal.
Trial summary
The goal of this clinical trial is to learn if transcutaneous auricular vagus nerve stimulation (taVNS) works to reduce perceived stress and psychological distress in university students with high distress levels. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Psychological Distress, Stress (Psychology), Perceived Stress
- What is being tested?
- taVNS
- Type of treatment
- Medical device
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 40 participants
- Where
- 1 sitePortugal
- Study dates
- 10 Jan 2025to 10 Jun 2025
- Phase
- Interventional
- Are there results?
- Yes, posted in the registrySummary in the doctors' view
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Being a university student
- Age ≥18 years
- High to very high levels of psychological distress (K10 score ≥22)
Who cannot join
- Psychotropic medication initiation or dose change within the last 3 months
- Substance dependence
- Current psychological or psychotherapeutic treatment
- Any formal mental disorder diagnosis
- Pregnancy
- History of dizziness or seizures
Show all 9Show fewer
- Cochlear implants
- Ear plastic surgery
- Auricular malformations
Trial locations and contacts
1 site in 1 country.
Portugal1 site
Egas Moniz School of Health & Science
Almada, Setúbal District, 2829 - 511
About this study
Official title: Effects of Transcutaneous Auricular Vagus Nerve Stimulation on Perceived Stress and Psychological Distress in University Students With High Distress Levels: A Randomized Blinded Clinical Trial
The goal of this clinical trial is to learn if transcutaneous auricular vagus nerve stimulation (taVNS) works to reduce perceived stress and psychological distress in university students with high distress levels. The main questions it aims to answer are:
- Does taVNS reduce perceived stress (measured by PSS-10) in university students with high psychological distress?
- Does taVNS reduce psychological distress (measured by K10) in university students with high psychological distress?
- Is the intervention feasible and tolerable for implementation in higher-education mental health support?
Read more
Researchers will compare taVNS (electrode placed on the left tragus) to a sham stimulation group (electrode placed on the left earlobe) to see if taVNS reduces stress and distress.
Participants will:
- Attend five consecutive daily 30-minute stimulation sessions
- Complete stress and distress questionnaires before the intervention, immediately after, and at 1-month follow-up
- Receive electrical stimulation at individually adjusted intensity using the Nurosym device (pulse width 250 µs, frequency 20 Hz).
Read the detailed description
Mental health is increasingly recognized as a core component of overall health, reflecting the capacity to regulate behavior, maintain daily functioning, and sustain satisfying interpersonal relationships. Chronic exposure to adverse circumstances, particularly prolonged stress, has been associated with mental health problems and contributes to the onset and maintenance of common psychological disorders.
University students are exposed to multiple risk stressors (psychological, academic, biological, lifestyle, social, and economic) associated with poorer well-being. The transition to higher education often coincides with entry into adulthood and is frequently described as a particularly demanding period in emotional and mental terms. Students commonly report high stress while adapting to academic demands that may exceed previously acquired skills and coping strategies. Stressors in this setting often include academic pressure, peer competition, ineffective time management, financial concerns, work-life conflicts, and mental overload from multiple responsibilities.
Sustained exposure to these stressors is associated with poorer learning performance, physical health problems, and sleep disturbances. High and persistent stress, especially when perceived as uncontrollable and excessive, is frequently associated with higher psychological distress among university students. In turn, psychological distress is associated with elevated anxiety and depressive symptoms, sleep problems, reduced self-esteem and self-efficacy, and in more severe presentations, with self-injury, suicidal ideation, substance use, and neglect of academic responsibilities.
International literature has reported high burden and, in some settings, worsening trends in university student mental health over the last decade, positioning it as a relevant public health concern. In the WHO World Mental Health International College Student Initiative, 93.7% of 20,842 students across 24 universities in nine countries experienced some level of stress. In Portugal, similar concerning patterns have been reported: at the University of Lisbon, one quarter of 7,756 students presented severe or very severe stress levels, and a further survey indicated that nearly half of 2,084 students reported psychological symptoms and about one quarter had considered suicide.
Multiple approaches have been used to address stress-related mental health problems in university students, including psychotropic medication, cognitive-behavioral therapy, mindfulness-based interventions, relaxation techniques, and biofeedback-based strategies. However, pharmacological approaches may be limited by side effects and other constraints, and many effective interventions require time, staffing, or infrastructure that can restrict scalability in academic settings. These limitations underscore the need to evaluate complementary interventions that are feasible, acceptable, and implementable in university contexts.
Intervention Rationale:
Non-invasive neuromodulation has emerged as a potential strategy for stress-related mental health problems. Neuromodulation broadly refers to the application of electrical, magnetic, vibratory, or ultrasonic stimuli to modify nervous system activity and regulate dysfunctional neural circuits. Within this domain, modulation of vagal pathways has received increasing attention because the vagus nerve contributes to autonomic balance by promoting parasympathetic activation and dampening sympathetic arousal, thereby supporting recovery after stress and emotional/physiological homeostasis. Disruption of this balance, marked by heightened sympathetic activation and reduced parasympathetic activity, has been associated with poorer physical and mental health outcomes.
Transcutaneous vagus nerve stimulation (tVNS) was developed as a less invasive alternative to implanted vagus nerve stimulation. Transcutaneous auricular vagus nerve stimulation (taVNS) targets the auricular branch of the vagus nerve using low-intensity electrical impulses applied to regions of the ear with dense vagal innervation, such as the tragus. By stimulating auricular vagal afferents, taVNS is proposed to engage stress and autonomic regulatory hubs (e.g., nucleus tractus solitarius, locus coeruleus), with downstream effects that may modulate autonomic stress-related physiology.
Consistent with this mechanistic rationale, taVNS has been investigated as a non-invasive strategy to reduce stress-related outcomes, including perceived stress and psychological distress. Available findings suggest potential benefits, but conclusions remain constrained by substantial heterogeneity in stimulation parameters, stimulation sites, and sham conditions. Brief, pragmatic protocols have yielded mixed but encouraging findings, including reductions in stress-related outcomes and anxiety in student samples, warranting further trials with standardized procedures and follow-up assessments. Importantly, evidence focused specifically on university students with elevated psychological distress remains limited, and many studies do not explicitly recruit or stratify participants using clinically meaningful distress thresholds.
Study Design:
This is a randomized, blinded clinical trial using convenience sampling of university students, randomly allocated to an experimental taVNS group or a sham (simulated stimulation) group. Assessments are conducted at three time points: pre-intervention (baseline), immediately post-intervention (after five sessions), and 1-month follow-up.
Participants:
Eligibility criteria include being a university student, aged ≥18 years, and assessed with high to very high levels of psychological distress (K10≥22). Exclusion criteria include psychotropic medication initiation or dose change within the last 3 months, substance dependence, current psychological or psychotherapeutic treatment, any formal mental disorder diagnosis, or contraindications for taVNS (e.g., pregnancy, history of dizziness or seizures, cochlear implants, ear plastic surgery, or auricular malformations). The study enrolled 40 participants, equally distributed across groups (n=20 per group).
Intervention Protocol:
The intervention consists of five consecutive daily 30-minute sessions delivered with the Nurosym device (preset pulse width 250 µs and frequency 20 Hz, with intensity adjusted to each participant's perception threshold). The only procedural difference between groups is electrode placement: in the taVNS group, the electrode is positioned on the left tragus, whereas in the sham group it is positioned on the left earlobe (a region with minimal vagal innervation).
Outcome Measures:
Perceived stress is assessed with the 10-item Perceived Stress Scale (PSS-10), scored 0 ("never") to 4 ("very often") and summed to a total score of 0-40, with higher scores indicating higher perceived stress. Psychological distress is assessed with the 10-item Kessler Psychological Distress Scale (K10), scored 1 ("never") to 5 ("always") with reference to the prior 30 days and summed to a total score of 10-50, with higher scores indicating higher distress. Internal consistency of the PSS-10 and K-10 will be evaluated at each time point using Cronbach's alpha.
A sociodemographic questionnaire is used to characterize the sample (age and sex) and to collect clinical information relevant to exclusion criteria (including medical comorbidities, psychotropic medication use, and participation in psychotherapeutic groups).
Procedures:
Recruitment is made via in-person classroom information sessions, and interested students receive a link to enroll. After providing informed consent, candidates complete the pre-intervention assessment protocol (sociodemographic questionnaire, PSS-10, and K10), and eligible participants are contacted by email to schedule sessions and randomly allocated to taVNS or sham by a draw. Before the first session, participants are re-asked about exclusion criteria to ensure ongoing eligibility.
After the fifth session, participants complete the post-intervention questionnaires (PSS-10 and K10) and are contacted by email 1 month later to complete the follow-up assessment.
After study completion and debriefing, participants originally assigned to the sham group were informed that they could, if they wished, receive active taVNS outside of the study procedures. This optional post-trial offer was not part of the clinical trial protocol, was not systematically documented as study data, and did not involve any formal cross-over within the trial.
Safety Monitoring:
Adverse events will be monitored before and after each session through visual inspection and participant self-report.
Statistical Analysis:
Analyses include internal consistency analyses (Cronbach's alpha), descriptive statistics, repeated-measures MANOVA with time (pre, post, follow-up) as the within-subject factor and group (taVNS vs sham) as the between-subject factor for two correlated dependent variables (PSS-10 and K10), followed by two repeated-measures ANOVAs (one per outcome) and Bonferroni-corrected pairwise comparisons across time points.
Ethics:
The study received approval from the institutional Ethics Committee (registration number 1328) and was conducted in accordance with the Declaration of Helsinki.
After the completion of the 1-month follow-up, participants originally assigned to the sham earlobe condition were offered optional taVNS with tragus placement outside the formal trial protocol.
Study Objectives:
This study aims to test whether a brief taVNS protocol reduces perceived stress and psychological distress in university students with high distress (K10 ≥ 22), assessed using the PSS-10 and K10 at baseline, post-intervention, and 1-month follow-up. The study also evaluates feasibility and tolerability to inform the translational potential of taVNS as a scalable adjunct within higher-education mental health support.
- Being tested
- taVNS, Sham
- Keywords
- Transcutaneous auricular vagus nerve stimulation, taVNS, Perceived stress, Psychological distress, University students, Neuromodulation, Mental health, Student well-being
- Medical subject headings
- Psychological Well-Being
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
taVNSDevice
Also called Auricular vagus nerve stimulation, Tragus stimulation
Non-invasive electrical stimulation delivered via the Nurosym device targeting the auricular branch of the vagus nerve. Electrode placement on the left tragus. Parameters: pulse width 250 µs, frequency 20 Hz, intensity individually adjusted to perception threshold. Five consecutive daily 30-minute sessions.
ShamDevice
Also called Earlobe stimulation
Non-invasive electrical stimulation delivered via the Nurosym device with electrode placement on the left earlobe. Identical parameters to active intervention (taVNS): pulse width 250 µs, frequency 20 Hz, intensity individually adjusted to perception threshold. Five consecutive daily 30-minute sessions.
| Study group | Role | What they receive |
|---|---|---|
| taVNS - Tragus Stimulation (Initial Treatment Only) | Experimental | Participants received only active taVNS during the randomized phase; no cross-over to other interventions occurred during the trial. Receives: Device: taVNS |
| Sham - Earlobe Stimulation (Initial Treatment Only) | Sham comparator | Participants received only sham stimulation during the randomized phase. No cross-over procedures were included in the registered study design or analyses. Receives: Device: Sham |
What is being measured
The primary outcome is the main question the study is designed to answer.
Psychological Distress (K10)
Psychological distress assessed using the 10-item Kessler Psychological Distress Scale (K10). Scored 1 ("never") to 5 ("always") with reference to the prior 30 days and summed to a total score of 10-50, with higher scores indicating higher distress.
Measured: Baseline (pre-intervention), immediately post-intervention (after 5 daily sessions, approximately day 5), and 1-month follow-up
Perceived Stress (PSS-10)
Perceived stress assessed using the 10-item Perceived Stress Scale (PSS-10). Scored 0 ("never") to 4 ("very often") and summed to a total score of 0-40, with higher scores indicating higher perceived stress.
Measured: Baseline (pre-intervention), immediately post-intervention (after 5 daily sessions, approximately day 5), and 1-month follow-up
Feasibility (Retention Rate)
Feasibility was assessed using retention of participants from baseline to the end of the study. For each arm, the number of randomized participants who completed all five stimulation sessions and the 1-month follow-up assessment was recorded.
Measured: From randomization through 1-month follow-up
Tolerability (Adverse Events / Dropout Due to AEs)
Tolerability was assessed by monitoring adverse events before and after each session through visual inspection of the stimulation site and open-ended participant self-report questioning. The number of participants who discontinued participation due to any adverse event was recorded.
Measured: From the first to the fifth stimulation session (Days 1-5), with adverse events assessed immediately before and after each intervention session.
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted17 Feb 2026
- Study start10 Jan 2025
- Primary completion17 Mar 2025
- Study completion10 Jun 2025
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Posted resultsParticipant flow, outcome measures and adverse events reported by the sponsor.
- Publications (11)Papers the sponsor has linked to this study.
- Other trials for Psychological DistressStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- Parallel assignment with blinded sham control. Participants are randomly allocated to receive either active transcutaneous auricular vagus nerve stimulation (taVNS) with electrode placement on the left tragus or sham stimulation with electrode placement on the left earlobe. Both groups receive identical stimulation parameters except for electrode location.
- Masking
- Double blind
- Who is masked
- Participant, Outcomes assessor
- Enrolment
- 40 participants (actual)
Sponsor and investigators
- Lead sponsor
- Egas Moniz - Cooperativa de Ensino Superior, CRL
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07411846
- Sponsor's protocol ID
- PT-280/24
- Acronym
- tAVNS4HES
- Status last verified
- Mar 2026
- First submitted
- 9 Feb 2026
- Last updated
- 8 Apr 2026
- Results posted
- Yes, on ClinicalTrials.gov
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No: Individual participant data (IPD) will not be shared because the informed consent obtained for this study did not include permission to share de-identified participant-level data with external researchers. If an ethics/IRB amendment and participant authorization (e.g., re-consent) are obtained in the future, the study team may update this record and make a de-identified dataset available under controlled access.
Publications
Badran BW, Dowdle LT, Mithoefer OJ, LaBate NT, Coatsworth J, Brown JC, DeVries WH, Austelle CW, McTeague LM, George MS. Neurophysiologic effects of transcutaneous auricular vagus nerve stimulation (taVNS) via electrical stimulation of the tragus: A concurrent taVNS/fMRI study and review. Brain Stimul. 2018 May-Jun;11(3):492-500. doi: 10.1016/j.brs.2017.12.009. Epub 2017 Dec 29.
PubMed 29361441Borges U, Pfannenstiel M, Tsukahara J, Laborde S, Klatt S, Raab M. Transcutaneous vagus nerve stimulation via tragus or cymba conchae: Are its psychophysiological effects dependent on the stimulation area? Int J Psychophysiol. 2021 Mar;161:64-75. doi: 10.1016/j.ijpsycho.2021.01.003. Epub 2021 Jan 11.
PubMed 33444689Bremner JD, Gurel NZ, Wittbrodt MT, Shandhi MH, Rapaport MH, Nye JA, Pearce BD, Vaccarino V, Shah AJ, Park J, Bikson M, Inan OT. Application of Noninvasive Vagal Nerve Stimulation to Stress-Related Psychiatric Disorders. J Pers Med. 2020 Sep 9;10(3):119. doi: 10.3390/jpm10030119.
PubMed 32916852Cuberos Paredes E, Goyes D, Mak S, Yardimian R, Ortiz N, McLaren A, Stauss HM. Transcutaneous auricular vagus nerve stimulation inhibits mental stress-induced cortisol release-Potential implications for inflammatory conditions. Physiol Rep. 2025 Feb;13(3):e70251. doi: 10.14814/phy2.70251.
PubMed 39936474Deuchars SA, Lall VK, Clancy J, Mahadi M, Murray A, Peers L, Deuchars J. Mechanisms underpinning sympathetic nervous activity and its modulation using transcutaneous vagus nerve stimulation. Exp Physiol. 2018 Mar 1;103(3):326-331. doi: 10.1113/EP086433. Epub 2017 Dec 3.
PubMed 29205954Dos Reis LD, Pereira Generoso L, Pereira GS, Teixeira Baru JPDS, Candido NL, Maziero Capello MG, de Castro ROM, Cardoso EJR, Scoz RD, Ferreira LMA, da Silva ML, da Silva JRT. Effects of multisession prefrontal cortex tDCS or taVNS on stress, perceived stress and sleep quality: a double-blind, randomized controlled study. Front Psychol. 2024 Sep 13;15:1343413. doi: 10.3389/fpsyg.2024.1343413. eCollection 2024.
PubMed 39346507Ferreira LMA, Brites R, Fraiao G, Pereira G, Fernandes H, de Brito JAA, Pereira Generoso L, Maziero Capello MG, Pereira GS, Scoz RD, Silva JRT, Silva ML. Transcutaneous auricular vagus nerve stimulation modulates masseter muscle activity, pain perception, and anxiety levels in university students: a double-blind, randomized, controlled clinical trial. Front Integr Neurosci. 2024 Jul 10;18:1422312. doi: 10.3389/fnint.2024.1422312. eCollection 2024.
PubMed 39051059Hernandez-Torrano D, Ibrayeva L, Sparks J, Lim N, Clementi A, Almukhambetova A, Nurtayev Y, Muratkyzy A. Mental Health and Well-Being of University Students: A Bibliometric Mapping of the Literature. Front Psychol. 2020 Jun 9;11:1226. doi: 10.3389/fpsyg.2020.01226. eCollection 2020.
PubMed 32581976Karyotaki E, Cuijpers P, Albor Y, Alonso J, Auerbach RP, Bantjes J, Bruffaerts R, Ebert DD, Hasking P, Kiekens G, Lee S, McLafferty M, Mak A, Mortier P, Sampson NA, Stein DJ, Vilagut G, Kessler RC. Sources of Stress and Their Associations With Mental Disorders Among College Students: Results of the World Health Organization World Mental Health Surveys International College Student Initiative. Front Psychol. 2020 Jul 30;11:1759. doi: 10.3389/fpsyg.2020.01759. eCollection 2020.
PubMed 32849042Kim AY, Marduy A, de Melo PS, Gianlorenco AC, Kim CK, Choi H, Song JJ, Fregni F. Safety of transcutaneous auricular vagus nerve stimulation (taVNS): a systematic review and meta-analysis. Sci Rep. 2022 Dec 21;12(1):22055. doi: 10.1038/s41598-022-25864-1.
PubMed 36543841Mofatteh M. Risk factors associated with stress, anxiety, and depression among university undergraduate students. AIMS Public Health. 2020 Dec 25;8(1):36-65. doi: 10.3934/publichealth.2021004. eCollection 2021.
PubMed 33575406
Study at a glance
From the registry record, last updated by the sponsor on 8 Apr 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Effects of Transcutaneous Auricular Vagus Nerve Stimulation on Perceived Stress and Psychological Distress in University Students With High Distress Levels: A Randomized Blinded Clinical Trial
- ClinicalTrials.gov ID
- NCT07411846
- Acronym / sponsor ID
- tAVNS4HES / PT-280/24
- Keywords
- Transcutaneous auricular vagus nerve stimulation, taVNS, Perceived stress, Psychological distress, University students, Neuromodulation, Mental health, Student well-being
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 40 participants (actual)
- Lead sponsor
- Egas Moniz - Cooperativa de Ensino Superior, CRLUniversity, hospital or other
- Study start
- 10 Jan 2025 (actual)
- Primary completion
- 17 Mar 2025 (actual)
- Study completion
- 10 Jun 2025 (actual)
- First posted
- 17 Feb 2026 (actual)
- Results
- Posted 8 Apr 2026
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The goal of this clinical trial is to learn if transcutaneous auricular vagus nerve stimulation (taVNS) works to reduce perceived stress and psychological distress in university students with high distress levels. The main questions it aims to answer are:
- Does taVNS reduce perceived stress (measured by PSS-10) in university students with high psychological distress?
- Does taVNS reduce psychological distress (measured by K10) in university students with high psychological distress?
- Is the intervention feasible and tolerable for implementation in higher-education mental health support?
Researchers will compare taVNS (electrode placed on the left tragus) to a sham stimulation group (electrode placed on the left earlobe) to see if taVNS reduces stress and distress.
Participants will:
- Attend five consecutive daily 30-minute stimulation sessions
- Complete stress and distress questionnaires before the intervention, immediately after, and at 1-month follow-up
- Receive electrical stimulation at individually adjusted intensity using the Nurosym device (pulse width 250 µs, frequency 20 Hz).
Detailed description
Mental health is increasingly recognized as a core component of overall health, reflecting the capacity to regulate behavior, maintain daily functioning, and sustain satisfying interpersonal relationships. Chronic exposure to adverse circumstances, particularly prolonged stress, has been associated with mental health problems and contributes to the onset and maintenance of common psychological disorders.
University students are exposed to multiple risk stressors (psychological, academic, biological, lifestyle, social, and economic) associated with poorer well-being. The transition to higher education often coincides with entry into adulthood and is frequently described as a particularly demanding period in emotional and mental terms. Students commonly report high stress while adapting to academic demands that may exceed previously acquired skills and coping strategies. Stressors in this setting often include academic pressure, peer competition, ineffective time management, financial concerns, work-life conflicts, and mental overload from multiple responsibilities.
Sustained exposure to these stressors is associated with poorer learning performance, physical health problems, and sleep disturbances. High and persistent stress, especially when perceived as uncontrollable and excessive, is frequently associated with higher psychological distress among university students. In turn, psychological distress is associated with elevated anxiety and depressive symptoms, sleep problems, reduced self-esteem and self-efficacy, and in more severe presentations, with self-injury, suicidal ideation, substance use, and neglect of academic responsibilities.
International literature has reported high burden and, in some settings, worsening trends in university student mental health over the last decade, positioning it as a relevant public health concern. In the WHO World Mental Health International College Student Initiative, 93.7% of 20,842 students across 24 universities in nine countries experienced some level of stress. In Portugal, similar concerning patterns have been reported: at the University of Lisbon, one quarter of 7,756 students presented severe or very severe stress levels, and a further survey indicated that nearly half of 2,084 students reported psychological symptoms and about one quarter had considered suicide.
Multiple approaches have been used to address stress-related mental health problems in university students, including psychotropic medication, cognitive-behavioral therapy, mindfulness-based interventions, relaxation techniques, and biofeedback-based strategies. However, pharmacological approaches may be limited by side effects and other constraints, and many effective interventions require time, staffing, or infrastructure that can restrict scalability in academic settings. These limitations underscore the need to evaluate complementary interventions that are feasible, acceptable, and implementable in university contexts.
Intervention Rationale:
Non-invasive neuromodulation has emerged as a potential strategy for stress-related mental health problems. Neuromodulation broadly refers to the application of electrical, magnetic, vibratory, or ultrasonic stimuli to modify nervous system activity and regulate dysfunctional neural circuits. Within this domain, modulation of vagal pathways has received increasing attention because the vagus nerve contributes to autonomic balance by promoting parasympathetic activation and dampening sympathetic arousal, thereby supporting recovery after stress and emotional/physiological homeostasis. Disruption of this balance, marked by heightened sympathetic activation and reduced parasympathetic activity, has been associated with poorer physical and mental health outcomes.
Transcutaneous vagus nerve stimulation (tVNS) was developed as a less invasive alternative to implanted vagus nerve stimulation. Transcutaneous auricular vagus nerve stimulation (taVNS) targets the auricular branch of the vagus nerve using low-intensity electrical impulses applied to regions of the ear with dense vagal innervation, such as the tragus. By stimulating auricular vagal afferents, taVNS is proposed to engage stress and autonomic regulatory hubs (e.g., nucleus tractus solitarius, locus coeruleus), with downstream effects that may modulate autonomic stress-related physiology.
Consistent with this mechanistic rationale, taVNS has been investigated as a non-invasive strategy to reduce stress-related outcomes, including perceived stress and psychological distress. Available findings suggest potential benefits, but conclusions remain constrained by substantial heterogeneity in stimulation parameters, stimulation sites, and sham conditions. Brief, pragmatic protocols have yielded mixed but encouraging findings, including reductions in stress-related outcomes and anxiety in student samples, warranting further trials with standardized procedures and follow-up assessments. Importantly, evidence focused specifically on university students with elevated psychological distress remains limited, and many studies do not explicitly recruit or stratify participants using clinically meaningful distress thresholds.
Study Design:
This is a randomized, blinded clinical trial using convenience sampling of university students, randomly allocated to an experimental taVNS group or a sham (simulated stimulation) group. Assessments are conducted at three time points: pre-intervention (baseline), immediately post-intervention (after five sessions), and 1-month follow-up.
Participants:
Eligibility criteria include being a university student, aged ≥18 years, and assessed with high to very high levels of psychological distress (K10≥22). Exclusion criteria include psychotropic medication initiation or dose change within the last 3 months, substance dependence, current psychological or psychotherapeutic treatment, any formal mental disorder diagnosis, or contraindications for taVNS (e.g., pregnancy, history of dizziness or seizures, cochlear implants, ear plastic surgery, or auricular malformations). The study enrolled 40 participants, equally distributed across groups (n=20 per group).
Intervention Protocol:
The intervention consists of five consecutive daily 30-minute sessions delivered with the Nurosym device (preset pulse width 250 µs and frequency 20 Hz, with intensity adjusted to each participant's perception threshold). The only procedural difference between groups is electrode placement: in the taVNS group, the electrode is positioned on the left tragus, whereas in the sham group it is positioned on the left earlobe (a region with minimal vagal innervation).
Outcome Measures:
Perceived stress is assessed with the 10-item Perceived Stress Scale (PSS-10), scored 0 ("never") to 4 ("very often") and summed to a total score of 0-40, with higher scores indicating higher perceived stress. Psychological distress is assessed with the 10-item Kessler Psychological Distress Scale (K10), scored 1 ("never") to 5 ("always") with reference to the prior 30 days and summed to a total score of 10-50, with higher scores indicating higher distress. Internal consistency of the PSS-10 and K-10 will be evaluated at each time point using Cronbach's alpha.
A sociodemographic questionnaire is used to characterize the sample (age and sex) and to collect clinical information relevant to exclusion criteria (including medical comorbidities, psychotropic medication use, and participation in psychotherapeutic groups).
Procedures:
Recruitment is made via in-person classroom information sessions, and interested students receive a link to enroll. After providing informed consent, candidates complete the pre-intervention assessment protocol (sociodemographic questionnaire, PSS-10, and K10), and eligible participants are contacted by email to schedule sessions and randomly allocated to taVNS or sham by a draw. Before the first session, participants are re-asked about exclusion criteria to ensure ongoing eligibility.
After the fifth session, participants complete the post-intervention questionnaires (PSS-10 and K10) and are contacted by email 1 month later to complete the follow-up assessment.
After study completion and debriefing, participants originally assigned to the sham group were informed that they could, if they wished, receive active taVNS outside of the study procedures. This optional post-trial offer was not part of the clinical trial protocol, was not systematically documented as study data, and did not involve any formal cross-over within the trial.
Safety Monitoring:
Adverse events will be monitored before and after each session through visual inspection and participant self-report.
Statistical Analysis:
Analyses include internal consistency analyses (Cronbach's alpha), descriptive statistics, repeated-measures MANOVA with time (pre, post, follow-up) as the within-subject factor and group (taVNS vs sham) as the between-subject factor for two correlated dependent variables (PSS-10 and K10), followed by two repeated-measures ANOVAs (one per outcome) and Bonferroni-corrected pairwise comparisons across time points.
Ethics:
The study received approval from the institutional Ethics Committee (registration number 1328) and was conducted in accordance with the Declaration of Helsinki.
After the completion of the 1-month follow-up, participants originally assigned to the sham earlobe condition were offered optional taVNS with tragus placement outside the formal trial protocol.
Study Objectives:
This study aims to test whether a brief taVNS protocol reduces perceived stress and psychological distress in university students with high distress (K10 ≥ 22), assessed using the PSS-10 and K10 at baseline, post-intervention, and 1-month follow-up. The study also evaluates feasibility and tolerability to inform the translational potential of taVNS as a scalable adjunct within higher-education mental health support.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind (participant, outcomes assessor)
- Number of arms
- 2
- Model description
- Parallel assignment with blinded sham control. Participants are randomly allocated to receive either active transcutaneous auricular vagus nerve stimulation (taVNS) with electrode placement on the left tragus or sham stimulation with electrode placement on the left earlobe. Both groups receive identical stimulation parameters except for electrode location.
| Arm | Type | Receives |
|---|---|---|
| taVNS - Tragus Stimulation (Initial Treatment Only) | Experimental | Device: taVNSParticipants received only active taVNS during the randomized phase; no cross-over to other interventions occurred during the trial. |
| Sham - Earlobe Stimulation (Initial Treatment Only) | Sham comparator | Device: ShamParticipants received only sham stimulation during the randomized phase. No cross-over procedures were included in the registered study design or analyses. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (3 listed)
- Being a university student
- Age ≥18 years
- High to very high levels of psychological distress (K10 score ≥22)
Key exclusion criteria (9 listed)
- Psychotropic medication initiation or dose change within the last 3 months
- Substance dependence
- Current psychological or psychotherapeutic treatment
- Any formal mental disorder diagnosis
- Pregnancy
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| taVNSAlso: Auricular vagus nerve stimulation, Tragus stimulationNon-invasive electrical stimulation delivered via the Nurosym device targeting the auricular branch of the vagus nerve. Electrode placement on the left tragus. Parameters: pulse width 250 µs, frequency 20 Hz, intensity individually adjusted to perception threshold. Five consecutive daily 30-minute sessions. | Device | taVNS - Tragus Stimulation (Initial Treatment Only) |
| ShamAlso: Earlobe stimulationNon-invasive electrical stimulation delivered via the Nurosym device with electrode placement on the left earlobe. Identical parameters to active intervention (taVNS): pulse width 250 µs, frequency 20 Hz, intensity individually adjusted to perception threshold. Five consecutive daily 30-minute sessions. | Device | Sham - Earlobe Stimulation (Initial Treatment Only) |
Primary outcome
Psychological Distress (K10)
Time frame: Baseline (pre-intervention), immediately post-intervention (after 5 daily sessions, approximately day 5), and 1-month follow-up
Psychological distress assessed using the 10-item Kessler Psychological Distress Scale (K10). Scored 1 ("never") to 5 ("always") with reference to the prior 30 days and summed to a total score of 10-50, with higher scores indicating higher distress.
Perceived Stress (PSS-10)
Time frame: Baseline (pre-intervention), immediately post-intervention (after 5 daily sessions, approximately day 5), and 1-month follow-up
Perceived stress assessed using the 10-item Perceived Stress Scale (PSS-10). Scored 0 ("never") to 4 ("very often") and summed to a total score of 0-40, with higher scores indicating higher perceived stress.
Feasibility (Retention Rate)
Time frame: From randomization through 1-month follow-up
Feasibility was assessed using retention of participants from baseline to the end of the study. For each arm, the number of randomized participants who completed all five stimulation sessions and the 1-month follow-up assessment was recorded.
Tolerability (Adverse Events / Dropout Due to AEs)
Time frame: From the first to the fifth stimulation session (Days 1-5), with adverse events assessed immediately before and after each intervention session.
Tolerability was assessed by monitoring adverse events before and after each session through visual inspection of the stimulation site and open-ended participant self-report questioning. The number of participants who discontinued participation due to any adverse event was recorded.
Results and safety
Loading the posted results from ClinicalTrials.gov…
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 8 Apr 2026.
- Posted resultsParticipant flow, baseline, all outcome measures and adverse events.
- Background: PubMed 29361441Badran BW, Dowdle LT, Mithoefer OJ, LaBate NT, Coatsworth J, Brown JC, DeVries WH, Austelle CW, McTeague LM, George MS. Neurophysiologic effects of transcutaneous auricular vagus nerve stimulation (taVNS) via electrical stimulation of the tragus: A concurrent taVNS/fMRI study and review. Brain Stimul. 2018 May-Jun;11(3):492-500. doi: 10.1016/j.brs.2017.12.009. Epub 2017 Dec 29.
- Background: PubMed 33444689Borges U, Pfannenstiel M, Tsukahara J, Laborde S, Klatt S, Raab M. Transcutaneous vagus nerve stimulation via tragus or cymba conchae: Are its psychophysiological effects dependent on the stimulation area? Int J Psychophysiol. 2021 Mar;161:64-75. doi: 10.1016/j.ijpsycho.2021.01.003. Epub 2021 Jan 11.
- Background: PubMed 32916852Bremner JD, Gurel NZ, Wittbrodt MT, Shandhi MH, Rapaport MH, Nye JA, Pearce BD, Vaccarino V, Shah AJ, Park J, Bikson M, Inan OT. Application of Noninvasive Vagal Nerve Stimulation to Stress-Related Psychiatric Disorders. J Pers Med. 2020 Sep 9;10(3):119. doi: 10.3390/jpm10030119.
- Background: PubMed 39936474Cuberos Paredes E, Goyes D, Mak S, Yardimian R, Ortiz N, McLaren A, Stauss HM. Transcutaneous auricular vagus nerve stimulation inhibits mental stress-induced cortisol release-Potential implications for inflammatory conditions. Physiol Rep. 2025 Feb;13(3):e70251. doi: 10.14814/phy2.70251.
- Background: PubMed 29205954Deuchars SA, Lall VK, Clancy J, Mahadi M, Murray A, Peers L, Deuchars J. Mechanisms underpinning sympathetic nervous activity and its modulation using transcutaneous vagus nerve stimulation. Exp Physiol. 2018 Mar 1;103(3):326-331. doi: 10.1113/EP086433. Epub 2017 Dec 3.
- Background: PubMed 39346507Dos Reis LD, Pereira Generoso L, Pereira GS, Teixeira Baru JPDS, Candido NL, Maziero Capello MG, de Castro ROM, Cardoso EJR, Scoz RD, Ferreira LMA, da Silva ML, da Silva JRT. Effects of multisession prefrontal cortex tDCS or taVNS on stress, perceived stress and sleep quality: a double-blind, randomized controlled study. Front Psychol. 2024 Sep 13;15:1343413. doi: 10.3389/fpsyg.2024.1343413. eCollection 2024.
- Background: PubMed 39051059Ferreira LMA, Brites R, Fraiao G, Pereira G, Fernandes H, de Brito JAA, Pereira Generoso L, Maziero Capello MG, Pereira GS, Scoz RD, Silva JRT, Silva ML. Transcutaneous auricular vagus nerve stimulation modulates masseter muscle activity, pain perception, and anxiety levels in university students: a double-blind, randomized, controlled clinical trial. Front Integr Neurosci. 2024 Jul 10;18:1422312. doi: 10.3389/fnint.2024.1422312. eCollection 2024.
- Background: PubMed 32581976Hernandez-Torrano D, Ibrayeva L, Sparks J, Lim N, Clementi A, Almukhambetova A, Nurtayev Y, Muratkyzy A. Mental Health and Well-Being of University Students: A Bibliometric Mapping of the Literature. Front Psychol. 2020 Jun 9;11:1226. doi: 10.3389/fpsyg.2020.01226. eCollection 2020.
- Background: PubMed 32849042Karyotaki E, Cuijpers P, Albor Y, Alonso J, Auerbach RP, Bantjes J, Bruffaerts R, Ebert DD, Hasking P, Kiekens G, Lee S, McLafferty M, Mak A, Mortier P, Sampson NA, Stein DJ, Vilagut G, Kessler RC. Sources of Stress and Their Associations With Mental Disorders Among College Students: Results of the World Health Organization World Mental Health Surveys International College Student Initiative. Front Psychol. 2020 Jul 30;11:1759. doi: 10.3389/fpsyg.2020.01759. eCollection 2020.
- Background: PubMed 36543841Kim AY, Marduy A, de Melo PS, Gianlorenco AC, Kim CK, Choi H, Song JJ, Fregni F. Safety of transcutaneous auricular vagus nerve stimulation (taVNS): a systematic review and meta-analysis. Sci Rep. 2022 Dec 21;12(1):22055. doi: 10.1038/s41598-022-25864-1.
- Background: PubMed 33575406Mofatteh M. Risk factors associated with stress, anxiety, and depression among university undergraduate students. AIMS Public Health. 2020 Dec 25;8(1):36-65. doi: 10.3934/publichealth.2021004. eCollection 2021.
- Individual participant dataSharing planned: No. Individual participant data (IPD) will not be shared because the informed consent obtained for this study did not include permission to share de-identified participant-level data with external researchers. If an ethics/IRB amendment and participant authorization (e.g., re-consent) are obtained in the future, the study team may update this record and make a de-identified dataset available under controlled access.
Related trials for Psychological Distress
Recruiting
The Trans-Led Care Study
Substance Abuse, Substance Addiction
Not yet recruiting
Hand in Hand: Feasibility of a Compassion-Focused App to Support Parents of Children With Mental Health Problems
Physiological Conditions, Distress, Emotional
Active, not recruiting
HRVB for Stress and Anxiety During Dentistry Students' Clinical Transition
Stress (Psychology), Anxiety
Recruiting
Effects of a Mindful Self-Compassion Intervention on Psychological Adjustment in Breast Cancer Survivors
Breast Cancer
Not yet recruiting
Group Psychological Intervention to Reduce Distress Among Nursing Undergraduates
Psychological Distress
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing taVNS in people with Psychological Distress and Stress (Psychology), run by Egas Moniz - Cooperativa de Ensino Superior, CRL at 1 site in Portugal.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 9 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 8 Apr 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Portugal. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Yes. Results are posted in the registry (first posted 8 Apr 2026). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Psychological Distress (K10) (time frame: Baseline (pre-intervention), immediately post-intervention (after 5 daily sessions, approximately day 5), and 1-month follow-up). The study lists 4 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT07411846, which also lists 11 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 8 Apr 2026.